Aptevo Therapeutics Inc Stock News

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTN, WISH, JWN, APVO, and BNGO. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.

Aptevo Therapeutics Inc. (NASDAQ:APVO) major shareholder Kevin C. Tang sold 369,533 shares of the companys stock in a transaction dated Thursday, November 18th. The shares were sold at an average price of $8.34, for a total transaction of $3,081,905.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is []

Equities analysts forecast that Aptevo Therapeutics Inc. (NASDAQ:APVO) will post $3.40 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aptevo Therapeutics earnings, with estimates ranging from $3.30 million to $3.50 million. The company is expected to report its next quarterly earnings report on Friday, February []

The trading price of Aptevo Therapeutics Inc. (NASDAQ:APVO) floating higher at last check on Tuesday, November 23, closing at $8.82, 36.11% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

The shares of Aptevo Therapeutics Inc (NASDAQ:APVO) are soaring today, up 35% to trade at $8.75 at last check, after the biotech concern announced that one high-risk cancer patient had a complete remi

The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by over 40% during intraday trading today. This is why it happened.

Aptevo Therapeutics Inc. (NASDAQ:APVO)s traded shares stood at 0.43 million during the last session, with the companys beta value hitting 6.78. At the close of trading, the stocks price was $7.30, to imply a decrease of -9.88% or -$0.8 in intraday trading. The APVO shares 52-week high remains $51.75, putting it -608.9% down since that Aptevo Therapeutics Inc. (NASDAQ: APVO) Has Decreased By -84.02 Percent This Year. Is It A Better Buy Than Others? Read More »

(PR-inside.com) SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced that the Company will present two abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually and in-person in Atlanta, Ga. December 11-14, 2021. Details of the presentations are as follows: Title: "Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS"Lead Author: Justin M. Watts, M.D., ..

SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology the

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for ta

Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was pu

SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ther

SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on i

Aptevo Therapeutics Inc. (APVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p